<DOC>
	<DOC>NCT00213278</DOC>
	<brief_summary>This study is examining whether Vinblastine is an effective drug to shrink low grade glioma brain tumors in children, and what the side effects are.</brief_summary>
	<brief_title>Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>&lt; 21 years of age at original diagnosis histological verification of low grade glioma (glial tumors, neuronal tumors or chiasmatichypothalamic tumor) at original diagnosis evidence of tumor recurrence or progression by MRI or contrast CT Karnofsky and Lansky performance status of 0,1 or 2 life expectancy of greater than or equal to 2 months adequate organ and bone marrow function within 7 days of starting treatment with Vinblastine absolute neutrophil count (ANC)&gt; 1000/uL platelet count &gt; 100,000/uL (transfusion independent) serum creatinine &lt; 1.5 x normal for age written informed consent signed by subject and/or subject's parent/legal guardian not recovered from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy chemotherapy within 2 weeks of entry in study (4 weeks if prior nitrosourea was used) less than 7 days since the completion of therapy with a biologic agent less than 2 months since cranial/spinal radiation receiving a stable dose of dexamethasone for less than one week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>glioma</keyword>
	<keyword>brain tumour</keyword>
	<keyword>cancer</keyword>
	<keyword>pediatrics</keyword>
	<keyword>vinblastine sulfate</keyword>
</DOC>